Nasal polyps are fleshy swellings that develop in the lining of the nose and paranasal sinuses, which are the air-filled spaces linked to the nasal cavity. They are noncancerous growths.

What you may think are allergies or a cold, could be the sign of nasal polyps. Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Nasal polyps can be a persistent issue for individuals suffering from chronic sinusitis, allergies, or fungal infections, often leading to breathing difficulties and discomfort. When medications ...

If approved, it will be the first biologic challenger to Dupixent ... The drug improved both the size of nasal polyps at week 52 and in nasal obstruction during weeks 49-52, compared to placebo ...

Chronic sinusitis can be caused by abnormal growths in the sinuses called nasal polyps, allergies, infections, or other medical conditions. If you've had symptoms for more than 12 weeks ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Nasal polyps. Allergic rhinitis: ≥12yrs: 2 sprays in each nostril once daily; prophylaxis: begin 2–4 weeks prior to anticipated start of pollen season. Nasal polyps: ≥18yrs: 2 sprays in ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent respiratory diseases.

CRSwNP is caused by chronic inflammation of the nasal lining that can cause soft tissue growth, known as nasal polyps, that develop in the sinuses and nasal cavity ... group and two in the mepolizumab ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...